This letter comments on the recently published manuscript by Huang et al in the World Journal of Gastroenterology,which focused on the immunomodulatory effect of Calculus bovis on hepatocellular carcinoma(HCC)tumor mi...This letter comments on the recently published manuscript by Huang et al in the World Journal of Gastroenterology,which focused on the immunomodulatory effect of Calculus bovis on hepatocellular carcinoma(HCC)tumor microenvironments(TME)by inhibiting M2-tumor-associated macrophage(M2-TAM)polarization via Wnt/β-catenin pathway modulation.Recent research highlights the crucial role of TAMs and their polarization towards the M2 phenotype in promoting HCC progression.Epigenetic regulation,particularly through microRNAs(miR),has emerged as a key factor in modulating immune responses and TAM polarization in the TME,influencing treatment responses and tumor progression.This editorial focuses on miR-206,which has been found to inhibit HCC cell proliferation and migration and promote apoptosis.Moreover,miR-206 enhances anti-tumor immune responses by promoting M1-polarization of Kupffer cells,facilitating CD8+T cell recruitment and suppressing liver cancer stem cell expansion.However,challenges remain in understanding the precise mechanisms regulating miR-206 and its potential as a therapeutic agent.Targeting epigenetic mechanisms and improving strategies,whether through pharmacological or genetic approaches,offer promising avenues to sensitize tumor cells to chemotherapy.Understanding the intricate interactions between cancer and non-coding RNA regulation opens new avenues for developing targeted therapies,potentially improving HCC prognosis.展开更多
目的探讨微小RNA-206(microRNA-206)对糖尿病肾病(DN)大鼠肾损伤的作用,及其可能机制。方法用高脂饲料+腹腔注射链脲佐菌素建立DN大鼠模型。将造模成功的DN大鼠随机分为模型组、microRNA-206沉默组和microRNA-206过表达组,每组15只;另...目的探讨微小RNA-206(microRNA-206)对糖尿病肾病(DN)大鼠肾损伤的作用,及其可能机制。方法用高脂饲料+腹腔注射链脲佐菌素建立DN大鼠模型。将造模成功的DN大鼠随机分为模型组、microRNA-206沉默组和microRNA-206过表达组,每组15只;另取15只正常大鼠设为空白组。microRNA-206沉默组大鼠尾静脉注射30 mg·kg^(-1)antagomicroRNA-206;microRNA-206过表达组大鼠尾静脉注射30 mg·kg^(-1)agomicroRNA-206;模型组和空白组大鼠均尾静脉注射等量的0.9%NaCl。4组大鼠每周给药1次,连续给药8周。用全自动生化分析仪检测血清肌酸酐(SCr)和24 h尿蛋白量(24 h UAER),用实时荧光定量聚合酶链反应法检测肾组织中microRNA-206的表达水平,用蛋白质印迹法检测肾组织中胰岛素样生长因子1(IGF-1)和酪氨酸激酶/信号转导与转录激活因子(JAK/STAT)信号通路相关蛋白的表达水平。结果microRNA-206过表达组、microRNA-206沉默组、模型组和空白组的血清SCr分别为(43.72±4.49),(91.24±10.06),(86.71±9.37)和(31.18±4.28)μmol·L^(-1),24 h UAER分别为(25.83±2.36),(39.61±4.42),(34.49±3.53)和(15.58±1.47)mg,microRNA-206表达量分别为0.65±0.07,0.28±0.03,0.43±0.04和1.00±0.00,IGF-1蛋白相对表达水平分别为0.27±0.03,0.44±0.04,0.35±0.04和0.19±0.02,p-STAT1/STAT1比值分别为0.53±0.05,1.22±0.12,0.75±0.08和0.36±0.04,p-JAK2/JAK2比值分别为0.23±0.02,0.68±0.07,0.35±0.04和0.12±0.01。microRNA-206沉默组和microRNA-206过表达组的上述指标与模型组比较,差异均有统计学意义(均P<0.05),microRNA-206过表达组的上述指标与microRNA-206沉默组比较,差异均有统计学意义(均P<0.05)。结论microRNA-206可能通过调控IGF-1表达和介导JAK/STAT信号通路减轻DN大鼠肾损伤。展开更多
目的探究血清microRNA-21(miR-21)、microRNA-193a-3p(miR-193a-3p)水平与结直肠癌患者手术预后的关系。方法回顾性分析2020年1月—2022年1月苏州大学附属第一医院收治112例结直肠癌患者的病历资料。患者均接受结直肠癌根治术,术后随访1...目的探究血清microRNA-21(miR-21)、microRNA-193a-3p(miR-193a-3p)水平与结直肠癌患者手术预后的关系。方法回顾性分析2020年1月—2022年1月苏州大学附属第一医院收治112例结直肠癌患者的病历资料。患者均接受结直肠癌根治术,术后随访16个月,记录患者的预后生存结局,多因素逐步Logistic回归分析结直肠癌患者手术预后的影响因素,评估血清miR-21、miR-193a-3p对结直肠癌患者预后的预测效能。结果112例结直肠癌患者死亡22例,病死率为19.64%;生存90例,生存率为80.36%。死亡组术前血清miR-21 mRNA相对表达量、临床分期Ⅲ期占比、淋巴结转移率均高于生存组(P<0.05),血清miR-193a-3p m RNA相对表达量低于生存组(P<0.05)。多因素逐步Logistic回归分析结果显示,临床分期Ⅲ期[OR=3.777(95%CI:1.399,10.194)]、淋巴结转移[OR=5.099(95%CI:1.715,15.156)]、miR-21表达升高[OR=4.889(95%CI:1.645,14.533)]、miR-193a-3p表达降低[OR=4.402(95%CI:1.481,13.084)]均是直肠癌患者预后的影响因素(P<0.05)。受试者工作特性曲线分析结果显示,血清miR-21、miR-193a-3p单一及联合预测结直肠癌预后的敏感性分别为69.04%(95%CI:0.487,0.813)、72.73%(95%CI:0.495,0.884)、86.36%(95%CI:0.640,0.964),特异性分别为62.22%(95%CI:0.513,0.720)、68.89%(95%CI:0.581,0.780)、90.00%(95%CI:0.814,0.950),曲线下面积分别为0.782、0.731和0.901。结论结直肠癌患者术前miR-21、miR-193a-3p表达与术后预后密切相关,且在结直肠癌患者的预后结局中表现出良好的预测效能。展开更多
文摘This letter comments on the recently published manuscript by Huang et al in the World Journal of Gastroenterology,which focused on the immunomodulatory effect of Calculus bovis on hepatocellular carcinoma(HCC)tumor microenvironments(TME)by inhibiting M2-tumor-associated macrophage(M2-TAM)polarization via Wnt/β-catenin pathway modulation.Recent research highlights the crucial role of TAMs and their polarization towards the M2 phenotype in promoting HCC progression.Epigenetic regulation,particularly through microRNAs(miR),has emerged as a key factor in modulating immune responses and TAM polarization in the TME,influencing treatment responses and tumor progression.This editorial focuses on miR-206,which has been found to inhibit HCC cell proliferation and migration and promote apoptosis.Moreover,miR-206 enhances anti-tumor immune responses by promoting M1-polarization of Kupffer cells,facilitating CD8+T cell recruitment and suppressing liver cancer stem cell expansion.However,challenges remain in understanding the precise mechanisms regulating miR-206 and its potential as a therapeutic agent.Targeting epigenetic mechanisms and improving strategies,whether through pharmacological or genetic approaches,offer promising avenues to sensitize tumor cells to chemotherapy.Understanding the intricate interactions between cancer and non-coding RNA regulation opens new avenues for developing targeted therapies,potentially improving HCC prognosis.
文摘目的探讨微小RNA-206(microRNA-206)对糖尿病肾病(DN)大鼠肾损伤的作用,及其可能机制。方法用高脂饲料+腹腔注射链脲佐菌素建立DN大鼠模型。将造模成功的DN大鼠随机分为模型组、microRNA-206沉默组和microRNA-206过表达组,每组15只;另取15只正常大鼠设为空白组。microRNA-206沉默组大鼠尾静脉注射30 mg·kg^(-1)antagomicroRNA-206;microRNA-206过表达组大鼠尾静脉注射30 mg·kg^(-1)agomicroRNA-206;模型组和空白组大鼠均尾静脉注射等量的0.9%NaCl。4组大鼠每周给药1次,连续给药8周。用全自动生化分析仪检测血清肌酸酐(SCr)和24 h尿蛋白量(24 h UAER),用实时荧光定量聚合酶链反应法检测肾组织中microRNA-206的表达水平,用蛋白质印迹法检测肾组织中胰岛素样生长因子1(IGF-1)和酪氨酸激酶/信号转导与转录激活因子(JAK/STAT)信号通路相关蛋白的表达水平。结果microRNA-206过表达组、microRNA-206沉默组、模型组和空白组的血清SCr分别为(43.72±4.49),(91.24±10.06),(86.71±9.37)和(31.18±4.28)μmol·L^(-1),24 h UAER分别为(25.83±2.36),(39.61±4.42),(34.49±3.53)和(15.58±1.47)mg,microRNA-206表达量分别为0.65±0.07,0.28±0.03,0.43±0.04和1.00±0.00,IGF-1蛋白相对表达水平分别为0.27±0.03,0.44±0.04,0.35±0.04和0.19±0.02,p-STAT1/STAT1比值分别为0.53±0.05,1.22±0.12,0.75±0.08和0.36±0.04,p-JAK2/JAK2比值分别为0.23±0.02,0.68±0.07,0.35±0.04和0.12±0.01。microRNA-206沉默组和microRNA-206过表达组的上述指标与模型组比较,差异均有统计学意义(均P<0.05),microRNA-206过表达组的上述指标与microRNA-206沉默组比较,差异均有统计学意义(均P<0.05)。结论microRNA-206可能通过调控IGF-1表达和介导JAK/STAT信号通路减轻DN大鼠肾损伤。
文摘目的探究血清microRNA-21(miR-21)、microRNA-193a-3p(miR-193a-3p)水平与结直肠癌患者手术预后的关系。方法回顾性分析2020年1月—2022年1月苏州大学附属第一医院收治112例结直肠癌患者的病历资料。患者均接受结直肠癌根治术,术后随访16个月,记录患者的预后生存结局,多因素逐步Logistic回归分析结直肠癌患者手术预后的影响因素,评估血清miR-21、miR-193a-3p对结直肠癌患者预后的预测效能。结果112例结直肠癌患者死亡22例,病死率为19.64%;生存90例,生存率为80.36%。死亡组术前血清miR-21 mRNA相对表达量、临床分期Ⅲ期占比、淋巴结转移率均高于生存组(P<0.05),血清miR-193a-3p m RNA相对表达量低于生存组(P<0.05)。多因素逐步Logistic回归分析结果显示,临床分期Ⅲ期[OR=3.777(95%CI:1.399,10.194)]、淋巴结转移[OR=5.099(95%CI:1.715,15.156)]、miR-21表达升高[OR=4.889(95%CI:1.645,14.533)]、miR-193a-3p表达降低[OR=4.402(95%CI:1.481,13.084)]均是直肠癌患者预后的影响因素(P<0.05)。受试者工作特性曲线分析结果显示,血清miR-21、miR-193a-3p单一及联合预测结直肠癌预后的敏感性分别为69.04%(95%CI:0.487,0.813)、72.73%(95%CI:0.495,0.884)、86.36%(95%CI:0.640,0.964),特异性分别为62.22%(95%CI:0.513,0.720)、68.89%(95%CI:0.581,0.780)、90.00%(95%CI:0.814,0.950),曲线下面积分别为0.782、0.731和0.901。结论结直肠癌患者术前miR-21、miR-193a-3p表达与术后预后密切相关,且在结直肠癌患者的预后结局中表现出良好的预测效能。